SemiEvolvedMamal

$CWBHF $MSOS. If true this is huge, will allow full spectrum. Cannabis Wire has learned that CMS will allow the hemp-derived CBD products in the pilot to contain up to 3 milligrams of THC. CMS will specifically allow “orally administered” CBD products containing up to “3 mg per serving of tetrohydrocannabinols (such as delta-8-tetrahyrdocannabinol, delta-10-tetrahyrdocannabinol, and tetrahydrocannabinolic acid),” a CMS spokesperson told Cannabis Wire. cannabiswire.com/newsletters/sc…

Are psychedelics better than antidepressants? New study says no eurekalert.org/news-releases/… jamanetwork.com/journals/jamap… With an innovative approach, scientists try to get around the problem of participant expectation in tests of psychedelics. Psychedelic-assisted therapy may be no more effective than traditional antidepressants when patients know what drugs they are actually taking, according to a first-of-its kind analysis that compared how well each type of drug worked for major depression. Psychedelic-assisted therapy has resisted placebo-controlled testing methods — the gold standard in clinical trial design. Due to their powerful subjective effects, nearly everyone in the trial knows whether they received a psychedelic or the placebo even if they are not told. But in trials of antidepressants, participants may not figure out whether they have received the drug or a placebo, which makes it hard to compare them with psychedelics. To get around this problem, researchers from UC San Francisco, UCLA, and Imperial College, London tried a different approach. They compared the results from psychedelic therapy trials to the results from so-called open-label trials of traditional antidepressants, in which the participants all knew they were getting an antidepressant. That way, both treatments benefitted equally from the positive effect of patients knowing that they were being given a drug instead of a placebo. The findings both surprised and disappointed them: there was virtually no difference. “Unblinding is the defining methodological problem of psychedelic trials. What I wanted to show is that even if you compare psychedelics to open-label antidepressants, psychedelics are still much better,” said Balázs Szigeti, PhD, a clinical data scientist at UCSF’s Translational Psychedelic Research Program, who led the study. “Unfortunately, what we got is the opposite result — that they are the same, which is very surprising given the enthusiasm around psychedelics and mental health.” Szigeti is the co-first author of the paper with Zachary J. Williams, MD, PhD, of UCLA; Hannah Barnett, MSc, of Imperial College, London is also an author. The study appeared March 18 in JAMA Psychiatry.

@JDerevyanny CY25 Revenue Per Share YoY (weighted avg. diluted shares out) in $MSOS (so far): $CXXIF +17.5% (+15.2% revs & -2.4M WADS) $GTBIF +5.6% (+3.4% revs & -5.1M WADS) $TCNNF -1.1% (-0.4% revs & +1.3M WADS) $CURLF -8.2% (-5.5% revs & +21.3M WADS) $CRLBF -11.9% (-9.5% revs & +9.5M WADS)